Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
RESEARCH TOOLSreports
SXTP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.22 - $12.45
Previous CloseN/A
Volume13.44M
Average Volume (3M)120.46K
Market Cap
$5.79M
Enterprise Value$11.16M
Total Cash (Recent Filing)$1.97M
Total Debt (Recent Filing)$154.25K
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Nov 13, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding4,104,469
10 Day Avg. Volume85,714
30 Day Avg. Volume120,462
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.93
Enterprise Value/Revenue11.62
Enterprise Value/Gross Profit40.22
Enterprise Value/Ebitda-1.46
Forecast
1Y Price Target
$7.00Price Target Upside379.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Drug ApprovalArakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, which is a rare seasonal disease.
Financial PerformanceProduct revenues showed a significant year-over-year increase, despite being supply-constrained.
Market OpportunityThe company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.
Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.
Bears Say
EarningsQ1 earnings per share were below estimates due to higher than forecast SG&A expenses.
EquityThe company raised a net $1.9 million of equity, extending its financial runway.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.22 and its highest was $12.45 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $5.79M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 13, 2025 which is in 70 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
60 Degrees Pharmaceuticals, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.24 by $0.08.
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.46.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 4,104,469 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
60 Degrees Pharmaceuticals, Inc. reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.24. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Technical Analysis
ETHZilla Corporation
―
Adial Pharmaceuticals
―
Silo Pharma
―
Alzamend Neuro
―
Dermata Therapeutics
―
Ownership Overview
2.05% Insiders
0.29% Mutual Funds
<0.01% Other Institutional Investors
97.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---